Sarepta Therapeutics (SRPT) Current Deferred Revenue (2010 - 2026)
Sarepta Therapeutics' quarterly Current Deferred Revenue came in at $116.0 million in Q1 2026, up 158.67% year-on-year from $44.9 million in Q1 2025, and down 73.83% quarter-over-quarter from $443.4 million in Q4 2025.
Sarepta Therapeutics has reported Current Deferred Revenue for 17 years, with the latest figure at $116.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 158.67% year-over-year to $116.0 million; the trailing twelve-month figure through Mar 2026 stood at $116.0 million (up 158.67% YoY), and the FY2025 full-year result was $443.4 million, up 240.4% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $116.0 million, down from $443.4 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $485.4 million in Q3 2025, with the low at $22.5 million in Q3 2023.
- Average Current Deferred Revenue over 5 years is $148.2 million, with a median of $89.2 million recorded in 2022.
- Year-over-year, Current Deferred Revenue slumped 74.79% in 2023 and soared 464.6% in 2024.
- Tracing SRPT's Current Deferred Revenue over 5 years: stood at $89.2 million in 2022, then plunged by 43.51% to $50.4 million in 2023, then jumped by 158.36% to $130.3 million in 2024, then jumped by 240.4% to $443.4 million in 2025, then sank by 73.83% to $116.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $116.0 million (Q1 2026), $443.4 million (Q4 2025), and $485.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 116.04 Mn |
| Dec 31, 2025 | 443.40 Mn |
| Sep 30, 2025 | 485.45 Mn |
| Jun 30, 2025 | 395.43 Mn |
| Mar 31, 2025 | 44.86 Mn |
| Dec 31, 2024 | 130.26 Mn |
| Sep 30, 2024 | 127.00 Mn |
| Jun 30, 2024 | 122.04 Mn |
| Mar 31, 2024 | 112.00 Mn |
| Dec 31, 2023 | 50.42 Mn |
| Sep 30, 2023 | 22.49 Mn |
| Jun 30, 2023 | 44.99 Mn |
| Mar 31, 2023 | 67.24 Mn |
| Dec 31, 2022 | 89.24 Mn |
| Sep 30, 2022 | 89.24 Mn |
| Jun 30, 2022 | 89.24 Mn |
| Mar 31, 2022 | 89.24 Mn |
| Dec 31, 2021 | 89.24 Mn |
| Sep 30, 2021 | 89.24 Mn |
| Jun 30, 2021 | 89.24 Mn |
| Mar 31, 2021 | 89.24 Mn |
| Dec 31, 2020 | 89.24 Mn |
| Sep 30, 2020 | 89.24 Mn |
| Jun 30, 2020 | 89.31 Mn |
| Mar 31, 2020 | 91.07 Mn |
| Dec 31, 2019 | 3.30 Mn |
| Sep 30, 2019 | 3.30 Mn |
| Jun 30, 2019 | 3.30 Mn |
| Mar 31, 2019 | 3.99 Mn |
| Dec 31, 2018 | 3.30 Mn |
| Sep 30, 2018 | 3.30 Mn |
| Jun 30, 2018 | 3.30 Mn |
| Dec 31, 2017 | 3.32 Mn |
| Sep 30, 2017 | 3.30 Mn |
| Jun 30, 2017 | 3.30 Mn |
| Mar 31, 2017 | 3.30 Mn |
| Dec 31, 2016 | 3.30 Mn |
| Sep 30, 2016 | 3.30 Mn |
| Jun 30, 2016 | 3.30 Mn |
| Mar 31, 2016 | 3.30 Mn |
| Dec 31, 2015 | 3.30 Mn |
| Sep 30, 2015 | 3.30 Mn |
| Jun 30, 2015 | 3.30 Mn |
| Mar 31, 2015 | 3.36 Mn |
| Dec 31, 2014 | 3.32 Mn |
| Sep 30, 2014 | 3.36 Mn |
| Jun 30, 2014 | 3.30 Mn |
| Mar 31, 2014 | 3.30 Mn |
| Dec 31, 2013 | 3.30 Mn |
| Sep 30, 2013 | 3.96 Mn |
| Jun 30, 2013 | 4.50 Mn |
| Mar 31, 2013 | 3.88 Mn |
| Dec 31, 2012 | 3.30 Mn |
| Mar 31, 2012 | 3.30 Mn |
| Dec 31, 2011 | 3.30 Mn |
| Sep 30, 2011 | 3.30 Mn |
| Jun 30, 2011 | 3.30 Mn |
| Dec 31, 2010 | 3.30 Mn |